AIP
ORIC icon

Ameritas Investment Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Ameritas Investment Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.6K Buy
5,413
+832
+18% +$9.45K ﹤0.01% 1898
2025
Q4 		$37.5K Hold
4,581
– – ﹤0.01% 2318
2025
Q3 		$55K Hold
4,581
– – ﹤0.01% 2058
2025
Q2 		$46.5K Sell
4,581
-1,451
-24% -$9.74K ﹤0.01% 2230
2025
Q1 		$33.7K Hold
6,032
– – ﹤0.01% 2320
2024
Q4 		$48.7K Hold
6,032
– – ﹤0.01% 2200
2024
Q3 		$61.8K Hold
6,032
– – ﹤0.01% 2069
2024
Q2 		$42.6K Buy
6,032
+2,809
+87% +$25.1K ﹤0.01% 2229
2024
Q1 		$44.3K Hold
3,223
– – ﹤0.01% 2220
2023
Q4 		$29.7K Hold
3,223
– – ﹤0.01% 2407
2023
Q3 		$19.5K Hold
3,223
– – ﹤0.01% 2549
2023
Q2 		$25K Buy
+3,223
New +$18.3K ﹤0.01% 2443
2022
Q2 		– Sell
-2,339
Closed -$12K – 3187
2022
Q1 		$12K Hold
2,339
– – ﹤0.01% 2741
2021
Q4 		$34K Hold
2,339
– – ﹤0.01% 2375
2021
Q3 		$49K Buy
2,339
+480
+26% +$9.73K ﹤0.01% 2167
2021
Q2 		$33K Hold
1,859
– – ﹤0.01% 2451
2021
Q1 		$46K Hold
1,859
– – ﹤0.01% 2132
2020
Q4 		$63K Buy
1,859
+1,090
+142% +$31.3K ﹤0.01% 1844
2020
Q3 		$19K Hold
769
– – ﹤0.01% 2408
2020
Q2 		$26K Buy
+769
New +$24.5K ﹤0.01% 2212

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Ameritas Investment Partners's ORIC Position: Q1 2026 in Review

Ameritas Investment Partners increased its Oric Pharmaceuticals (ORIC) stake by 18% in Q1 2026, buying an estimated $9.45K and bringing the position to 5,413 shares worth $68.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1898.

Ameritas Investment Partners first reported a position in ORIC in Q2 2020 and has held it in 20 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Ameritas Investment Partners held 5,413 shares of Oric Pharmaceuticals worth $68.6K as of Q1 2026.
  • Ameritas Investment Partners bought 832 Oric Pharmaceuticals shares in Q1 2026, an estimated $9.45K.
  • Oric Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1898 holding.
  • Ameritas Investment Partners first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 20 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.